Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib in Young Adults With Moderate to Severe Skin Involvement Due to Lupus
NCT03288324Phase 2Completed
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- Aug 2017
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tofacitinib in cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE), sponsored by Cincinnati Children's Hospital Medical Center. Primary endpoint: Oral Clearance at Day 5. Started Aug 2017; status: completed.
02
Drugs
03
Conditions
cutaneous lupus erythematosus (CLE)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT03288324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03288324.